INTRODUCTION
Breast cancer is the most common female cancer worldwide, and the incidence of this malady has been continuously increasing in Korea, probably due to the westernization of life style. However, the age distribution of breast cancer patients in Korea is quite different from that of Western countries; about 60 percents of newly diagnosed breast cancer patients are premenopausal, while the premenopausal patients in Western countries constitute only 25 percents of all the breast cancer patients. (1) (2) (3) Many studies have shown that young breast cancer patients have a worse prognosis compared with older patients.(4-7) The poor prognosis of young breast cancer patients is due to advanced disease, poor differentiation, a lesser expression of estrogen receptor (ER) or progesterone receptor (PR), a higher nuclear grade and a higher rate of tumor proliferation and tamoxifen resistance. (4, 5, (7) (8) (9) In 2005 at the St. Gallen consensus meetings, young age (<35 yr) was adopted as one of the important factors to categorize the risk of recurrence, and chemotherapy was considered as one of the most important strategies to improve the survival of young premenopausal breast cancer patients. (10, 11) Despite the benefit of adjuvant chemotherapy, it could provoke premature menopause and menopausal sympPurpose: Although adjuvant chemotherapy improves the survival of premenopausal breast cancer patients, it could induce the premature menopause. The objective of this study was to investigate the incidence and risk factors of chemotherapy-induced amenorrhea (CIA) and recovery for young (< 45-year-old) breast cancer patients. Methods: We examined patients with primary invasive breast cancer who had been treated with surgery and adjuvant chemotherapy from January 2003 to June 2006. All of the patients were younger than 45 year and they had regular menstruation at the time of diagnosis. Amenorrhea was defined as the absence of menstruation for three consecutive months or a serum follicular stimulating hormone level > 30 mIU/mL. Results: A total of 324 patients were included in this study. Of these patients, 261 patients (80.6%) developed amenorrhea just after the completion of chemotherapy. During follow-up, 77 patients (29.5%) resumed menstruation. Amenorrhea rates at 6, 12, 24, and 36 months after chemotherapy were 72.2%, 66.6%, 58.1%, and 55.5%. Women who recovered from amenorrhea were significantly younger than the women who did not recover (p<0.001). Patients treated with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) less frequently recovered from amenorrhea than patients who were treated with anthracycline or taxane-based chemo-therapy (p<0.001). Conclusion: The age of the patient was the most important factor for the development of CIA. Patients treated with a CMF regimen and older patients showed poor recovery from CIA. These results could be helpful to make decisions about the treatment strategies for premenopausal young women. We conducted this study to investigate the incidence and risk factors for the occurrence of CIA and the recovery from it in young (<45 yr) breast cancer patients.
METHODS
We retrospectively studied those patients younger than The student t-test was used to evaluate the differences in the BMI and age at the time of diagnosis between the groups. The effects of other covariates on CIA were calculated using the Chi-square test. The risk factors for the recovery from amenorrhea were evaluated using the Kaplan-Meier method with the logistic regression model and the Cox proportional hazard model. Statistical analysis was done using SPSS software (version 14.0). All comparisons were considered significant at p-values <0.05.
RESULTS

Clinical characteristics of patients
A total of 324 patients were included in this study. The mean age of the patients was 40.1 yr (range: 26-44 yr).
The median follow up period was 31.3 months (range: 6-55 months) ( Table 1 ).
The chemotherapy regimens of the 324 patients were cyclophosphamide/methotrexate/5-fluorouracil (CMF) (n=242), doxorubicin/cyclophosphamide (AC) followed by taxane (n=34), AC (n=28), anthracycline plus taxane Chemotherapy-induced Amenorrhea in Young Breast Cancer Patients 21 who recovered from amenorrhea were significantly younger than those who did not (p<0.001, Figure 2 ). The patients treated with CMF showed the poorest recovery from amenorrhea (p<0.001, Figure 3 ). At 0, 6, 12, 24, and 36 months after completion of CMF, the rates of amenorrhea were 81.8%, 77.7%, 74.3%, 69.9%, and 68.0%, respectively. In contrast, the rates of amenorrhea at 0, 6, 12, 24, and 36 months after anthracycline or taxanebased chemotherapy were 78.0%, 53.7%, 41.5%, 25.3%, and 22.0%, respectively. A difference in the rates of recovery from CIA between the CMF group and the anthracycline or taxane-based group was observed for the both patient group that was <40 yr old and for the group that was ≥40 yr old ( Figure 4 ). The hormonal receptor status, hormonal therapy, radiotherapy and BMI had no effect on the resumption of menstruation. Age and chemotherapy regimen was evaluated using multivariate Cox proportional hazards models. On the multivariable analysis, the age of the patients and the chemotherapy regimen were significantly associated with the recovery from CIA (Table 4) .
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DISCUSSION
The reported incidence of amenorrhea after chemotherapy has widely varied in a range from 20% to 100%,(14- 
CONCLUSION
The age of a patient at the time of diagnosis was the most important factor for inducing CIA. The patient treated with CMF and the older premenopausal patients recovered poorly from CIA. These results could be helpful to make decisions about the treatment strategies for premenopausal young women, and these results can also aid physicians who are attempting to balance the risk of breast cancer recurrence with the risk of ovarian failure.
